News
Public · Published
Genmab says head and neck cancer drug cuts death risk by 50% with Merck's Keytruda
Genmab said its drug petosemtamab, given with Merck's Keytruda, cut the risk of death by 50% in certain head and neck cancer patients in a Phase 3 trial. The company plans to share full results with regulators.
Published:
Updated:
What happened
Genmab said its drug petosemtamab, given with Merck's Keytruda, cut the risk of death by 50% in certain head and neck cancer patients in a Phase 3 trial. The company plans to share full results with regulators.
Confirmed
Global impact / market context
A 50% lower risk of death, if confirmed by regulators, could make this combination a new first-choice treatment, which means more revenue for Genmab and Merck and a setback for rivals like Bicara developing similar drugs.
Analyst inference
The opposite share moves show investors see this as a competitive win for Genmab and Merck. Bicara's fall suggests its own Keytruda-based head and neck cancer program may now face a tougher path to standing out.
Analyst inference
What to watch
- Genmab plans to present full trial results at a future medical event and share them with global regulatory authorities, which means a filing review could follow. Confirmed
- Watch whether regulators accept the Phase 3 data for review and whether the 50% death-risk reduction holds across patient subgroups once full results are presented. Proposed
- Track Bicara's response, since a sharp share drop may reflect investor worry that its rival therapy will struggle to show similar survival benefits. Analyst inference